ClinicalTrials.gg
RecruitingNCT06832761LIGHTUpdated Oct 15, 2026

Lifestyle Intervention in the Memory Clinics of General and Academic Hospitals Trial

An interventional study of Personalized lifestyle intervention in Lifestyle Intervention, Lifestyle Risk Reduction and Cognitive Decline, sponsored by Maastricht University Medical Center. Recruiting at 2 sites in Netherlands. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Maastricht University Medical Center · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.
Updated Oct 15, 2026Site recruiting status changedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

Lifestyle Intervention in the memory clinics of General and academic Hospitals Trial (LIGHT) is a multi-center, randomized, controlled, lifestyle intervention trial among 300 older adults (≥50 years) with subjective cognitive decline (SCD) and mild cognitive impairment (MCI) at risk of dementia. Participants are randomized in a 1:1 ratio to Group A (tailored lifestyle intervention) or Group B (general health advice) for a duration of 12 months. The lifestyle intervention comprises three parts 1) Lifestyle coaching, 2) a voucher program, and 3) online self-management. Group B will receive general health advice.

Read the detailed description

Rationale: Dementia prevention through lifestyle has much potential but is not implemented in routine care. Patients referred to memory clinics, such as people with mild cognitive impairment (MCI) and subjective cognitive disorder (SCD), are at high risk for dementia and tend to have a worse health and lifestyle profile. While they might greatly benefit from lifestyle changes, there is no offer to help them make those changes.

Objective: The primary objectives are to examine both the (cost-)effectiveness of an innovative 1-year lifestyle intervention on lifestyle change measured by the validated Lifestyle for Brain Health Score (LIBRA) in older adults with SCD or MCI; and to identify possibilities, barriers, and facilitators for sustainable implementation of the lifestyle intervention.

Study design: Multicenter, randomized controlled trial comparing a lifestyle intervention with care as usual and general health advice.

Study population: 300 older adults (≥50 years) with SCD and MCI at risk of dementia.

Intervention: Participants are randomly allocated on a 1:1 ratio to participate either in Group A (tailored lifestyle intervention) or Group B (general health advice) for a duration of 12 months. The lifestyle intervention comprises three parts 1) Lifestyle coaching, 2) a voucher program, and 3) online self-management. Group B will receive general health advice.

Main study parameters/endpoints: The primary outcome will be change in participants' dementia risk profile as measured by the LIBRA score between baseline and 12 months. Secondary outcomes include cognitive functions (episodic memory, executive functions, information processing speed and attention). Other secondary outcomes include measures of body mass index (height and weight), office systolic and diastolic blood pressure, and lab measures including cholesterol levels (total, HDL, LDL, triglycerides), HbA1c levels, creatinine-based eGFR levels. Smoking, alcohol intake and current relevant medical conditions (coronary heart disease, kidney disease, type 2 diabetes, depression, hearing loss, sleep disorders) will be assessed through self-report. Additional questionnaires include health-related quality of life and capabilities, instrumental activities of daily living, health locus of control, self-efficacy, mastery, healthy diet, physical activity, cognitive stimulation, stress, and depressive symptoms, sleep quality, social support and feelings of loneliness, and lastly knowledge on dementia risk and protective factors. For cost-effectiveness, questionnaires on resource utilization, medical consumption, and productivity costs are administered. Additional measures include change in diagnosis (if applicable), demographics (age, sex, educational level, socioeconomic position (household income), paid/voluntary work hours, ethnicity, marital status, living situation), medication use, hearing loss. For process evaluation, questionnaires and interviews are administered on implementation, mechanisms of impact and contact (e.g., appointments with lifestyle coach, use of the breinzorg.nl self-management tool, use of the voucher program, experiences and usefulness, etc.).

02

Conditions studied

  • Lifestyle Intervention
  • Lifestyle Risk Reduction
  • Cognitive Decline
  • Dementia

Keywords

  • Lifestyle intervention
  • Risk reduction
  • Dementia
  • Memory clinic
03

In context

Risk Reduction Behavior

291 studies on the registry are indexed under Risk Reduction Behavior; 38 are open to participants now.

This study's planned enrollment of 300 is above the median of 201 across 250 interventional studies indexed under Risk Reduction Behavior.

Browse Risk Reduction Behavior studies →

Lead sponsor

Maastricht University Medical Center is the lead sponsor of 854 studies on the registry; 114 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥50 years of age at pre-screening;
  • Having a diagnosis of SCD or MCI;
  • Presence of ≥ 2 modifiable risk factors for dementia.

Exclusion criteria

Exclusion Criteria:

  • Having a diagnosis of dementia;
  • Insufficient understanding of the Dutch language;
  • Conditions affecting safe and continuous engagement in the intervention (e.g. under treatment for current malignant diseases, major psychiatric disorders (e.g. major depression, psychosis, bipolar disorder), other conditions preventing co-operation as judged by the local study nurse or consulted physician at the local study site;
  • Participation in any other research intervention trial at time of pre-screening and throughout the study period.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Lifestyle intervention (Group A)

    Group A receives a personalized lifestyle intervention.

    Behavioral: Personalized lifestyle intervention

  • No intervention
    Regular healthcare (Group B)

    Group B receives regular health care and a folder with general information on lifestyle and dementia risk reduction.

Interventions

  • BehavioralPersonalized lifestyle intervention

    The lifestyle intervention in Group A comprises three parts (1) three individual consultations with a trained lifestyle coach, (2) a voucher program to encourage brain healthy activities, and (3) access to an online self-management tool for dementia risk reduction (www.breinzorg.nl).

06

What researchers measure

Primary outcomes

  1. Lifestyle for BRAin Health (LIBRA) score 2

    1-year change in the Lifestyle for BRAin Health (LIBRA) score 2. This is a weighted score of fifteen lifestyle-related risk factors that are proven to be associated with increased dementia risk. Higher score means a greater risk for dementia. Scored from -6.1 to 25.8 (absolute weight).

    Time frame: 1 year

Secondary outcomes

  1. 15-Word Verbal Learning Test

    Measure of immediate and delayed memory. Wordlist is presented five times in a row and asked to be recalled immediately and after 15 minutes. Discrete number; score: 0-15 (higher score means a better outcome)

    Time frame: 1 year

  2. Digit Symbol Substitution Test (DSST)

    Measure of attention/processing speed, number of correctly matched symbols to digits within 90 seconds. Discrete number; 0-90 (higher score means a better outcome).

    Time frame: 1 year

  3. Wechsler Adult Intelligent Scale (WAIS) digit span

    Measure of working memory. Scored as the maximum number of digits repeated correctly. Discrete number; 0-14 (higher score means a better outcome).

    Time frame: 1 year

  4. Trail Making Test

    Measure of attention and executive function. Task A and B. Time taken to complete the test; minimum 0, no maximum, lower score means a better outcome.

    Time frame: 1 year

  5. Semantic Fluency Test

    Measure of language fluency. Semantic fluency test with category animals at baseline and professions at follow-up. Word count in one minute; minimum 0, no maximum, higher score means a better outcome.

    Time frame: 1 year

  6. EuroQol-5D-5L

    Quality of life, score 0-100, higher scores indicate better quality of life

    Time frame: 1 year

  7. ICEpop CAPability measure for Older people (ICECAP-O)

    Capabilities, score 0-1, higher scores indicate greater capabilities.

    Time frame: 1 year

  8. Health locus of Control Scale

    3 subscales, where each subscale ranges from 6 (minimum score) to 36 (maximum score). Higher scores indicate higher health locus of control.

    Time frame: 1 year

  9. General Self-Efficacy scale

    Total score ranges from 10 (minimum score) to 40 (maximum score), with higher scores representing higher self-efficacy.

    Time frame: 1 year

  10. Pearlin Mastery Scale

    Total score ranges from 7 (minimum score) to 28 (maximum score), where higher scores indicate greater levels of mastery.

    Time frame: 1 year

  11. Cholesterol

    Total, HDL, LDL and triglycerides in plasma (mmol/L).

    Time frame: 1 year

  12. Hemoglobin A1c

    Hemoglobin A1C (HbA1c) measured in plasma (%), indicates plasma glucose as a measure for diabetes status

    Time frame: 1 year

  13. Estimated glomerular filtration rate (eGFR)

    Creatinine-based (as measured in plasma) estimated glomerular filtration rate (eGFR) (healthy level: higher than 60) indicating kidney function.

    Time frame: 1 year

  14. Body mass Index (BMI)

    As calculated from weight (kg) and height (m), weight / height \^2

    Time frame: 1 year

  15. Blood pressure

    Scores range from approximately (for diastolic) 60-120 and (for systolic) 100-180 mmHg, with higher measures indicating higher blood pressure.

    Time frame: 1 year

  16. Medical history

    History of diabetes, coronary heart disease, kidney disease, hypertension, dyslipidemia, depression, hearing loss, poor vision, sleep disorders (asked in interview)

    Time frame: 1 year

  17. Amsterdam-Instrumental Activities Daily Living (ADL) Questionnaire

    Total scores range approximately 20-70, higher scores indicate better ADL functioning.

    Time frame: 1 year

  18. Mediterranean Diet Adherence Screener (MEDAS)

    Total score ranges from 0 (minimum score) to 14 (maximum score), with higher scores indicating higher adherence to Mediterranean diet.

    Time frame: 1 year

  19. Investigation into Cancer and Nutrition (EPIC) physical activity questionnaire

    Physical activity, uses Cambridge Physical Activity Index to categorize into 4 levels based on occupational and leisure-time activities.

    Time frame: 1 year

  20. Cognitive and Leisure Activities Scale

    The score ranges from 0 (minimum score) to 45 (maximum score), with higher scores representing higher cognitive and leisure activities.

    Time frame: 1 year

  21. Perceived Stress Scale

    Total score, scale 0 - 40, higher scores indicate more perceived stress.

    Time frame: 1 year

  22. Patient Health Questionnaire (PHQ)-9

    Total score ranges from 0 (minimum score) to 27 (maximum score), with higher scores representing a worse outcome (more depressive symptoms).

    Time frame: 1 year

  23. Groningen Sleep Quality Scale (GSKS)

    The score ranges from 0 (minimum score) to 14 (maximum score), with higher scores representing a worse outcome (worse sleep quality)

    Time frame: 1 year

  24. 6-item Lubben social network Scale

    The score ranges from 0 (minimum score) to 30 (maximum score), with higher scores meaning a better outcome (higher level of perceived social support)

    Time frame: 1 year

  25. De Jong Gierveld 6-item Scale

    The score ranges from 0 (minimum score) to 6 (maximum score), with higher scores representing a worse outcome (higher loneliness scores).

    Time frame: 1 year

  26. Knowledge on dementia risk questionnaire

    Measure awareness on risk and protective factors, higher score indicates better knowledge (0-25).

    Time frame: 1 year

  27. Smoking

    Duration (current/history) and quantity

    Time frame: 1 year

  28. Alcohol intake

    Measured in duration (current/history) and quantity

    Time frame: 1 year

  29. Medical Consumption Questionnaire (iMCQ)

    Medical consumption, selection of specific questions on care use such as GP visits and dietician. Used to calculate overall costs of medical care to define the cost-effectiveness of the intervention. Lower costs is a better score.

    Time frame: 1 year

  30. Productivity Costs Questionnaire (iPCQ)

    Measures productivity costs, used to calculate cost-effectiveness of the intervention. Higher productivity and lower costs is a better score.

    Time frame: 1 year

  31. Adherence

    Appointments missed, personal goals reached in coaching sessions (number), vouchers used (number), usage log of breinzorg.nl self-management tool (time active, modules completed). Together, they will be used in a model to calculate cost-effectiveness of the intervention based on the adherence.

    Time frame: 1 year

Other outcomes

  1. Biomarkers

    Plasma samples will be stored to later assess biomarkers. For example amyloid, p-tau, NFL, GFAP, BDNF.

    Time frame: 1 year

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Deckers K, Zwan MD, Soons LM, Waterink L, Beers S, van Houdt S, Stiensma B, Kwant JZ, Wimmers SCPM, Heutz RAM, Claassen JAHR, Oosterman JM, de Heus RAA, van de Rest O, Vermeiren Y, Voshaar RCO, Smidt N, Broersen LM, Sikkes SAM, Aarts E; MOCIA consortium; FINGER-NL consortium; Kohler S, van der Flier WM. A multidomain lifestyle intervention to maintain optimal cognitive functioning in Dutch older adults-study design and baseline characteristics of the FINGER-NL randomized controlled trial. Alzheimers Res Ther. 2024 Jun 13;16(1):126. doi: 10.1186/s13195-024-01495-8. PubMed 38872204 ↗
  • Rosenau C, Kohler S, Soons LM, Anstey KJ, Brayne C, Brodaty H, Engedal K, Farina FR, Ganguli M, Livingston G, Lyketsos CG, Mangialasche F, Middleton LE, Rikkert MGMO, Peters R, Sachdev PS, Scarmeas N, Salbaek G, van Boxtel MPJ, Deckers K. Umbrella review and Delphi study on modifiable factors for dementia risk reduction. Alzheimers Dement. 2024 Mar;20(3):2223-2239. doi: 10.1002/alz.13577. Epub 2023 Dec 30. PubMed 38159267 ↗
  • van Gils V, Waterink L, Wimmers SCPM, Jelsma JGM, de Vugt ME, Handels R, Sikkes SAM, van der Flier WM, Deckers K, Zwan MD, Kohler S, Janssen N. The Lifestyle Intervention in memory clinics of General and academic Hospitals Trial (LIGHT): Rationale and study design of a randomized controlled trial to reduce modifiable dementia risk. Alzheimers Res Ther. 2026 Jan 8;18(1):31. doi: 10.1186/s13195-025-01947-9. PubMed 41508135 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Feb 2028, 37 months after the start.

Of 167 non-industry interventional studies with no phase under Risk Reduction Behavior, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 42. This study's planned 37 months is above that.

Counting every sponsor, half of 169 studies reached it within 25 months; a quarter within 13 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Dec 2027 → Feb 2028 and completion Dec 2027 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2024
First posted
Feb 18, 2025
StartActual
Jan 27, 2025
Primary completionEst.
Feb 2028was Dec 2027
CompletionEst.
Feb 2028was Dec 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Alzheimer Center Amsterdam is now Completed
Oct 15, 2026
Primary completion
Dec 2027→Feb 2028
Oct 15, 2026
Study completion
Dec 2027→Feb 2028
Oct 15, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41508135 ↗
Oct 15, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Alzheimer Center Amsterdam · Amsterdam, NetherlandsContact removed l•••@amsterdamumc.nlContact removed (no phone or email listed)
  • Maastricht University · Maastricht, NetherlandsContact person changed (no phone or email listed)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41508135 ↗
    Alzheimer Center Amsterdam is now Completed
    Primary completion Dec 2027→Feb 2028
    Study completion Dec 2027→Feb 2028
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Alzheimer Center Amsterdam · Amsterdam, NetherlandsContact removed l•••@amsterdamumc.nlContact removed (no phone or email listed)
    • Maastricht University · Maastricht, NetherlandsContact person changed (no phone or email listed)
    + 4 other changes: index terms, identifiers, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06832761
Collaborators
Amsterdam UMC, location VUmc, InHolland University of Applied Sciences
Responsible party
Sponsor
First posted
Feb 18, 2025
Start date
Jan 27, 2025
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

Niels Janssen, PhD
Contact
n.janssen@maastrichtuniversity.nl
+316 14348188
Veerle van Gils, PhD
Contact
v.vangils@maastrichtuniversity.nl
+316 14348188
Sebastian Köhler, Professor
principal investigator · Maastricht University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion